Literature DB >> 23912797

Macular pigment in ophthalmic practice; a survey.

Ian J Murray1, Batul Hassanali, David Carden.   

Abstract

BACKGROUND: Macular pigment (MP) might provide some protection against age-related eye disease, and it is now being measured in ophthalmic practice. The purpose of the survey described here was to determine the distribution of MP in a random population of patients in a typical UK ophthalmic practice.
METHODS: Macular pigment optical density (MPOD) was measured in 56 patients aged 11 to 87 years, mean 52 ± 19, over a 3-month period. Typically, the test requires setting flicker thresholds for a centrally and peripherally viewed blue/green alternating target. Here we describe the results when an age-based estimate of the peripheral value is used, thus avoiding the peripheral setting. In 32 observers, a comparison was made between this and values obtained with the centre and periphery method. Information on smoking habits, iris colour, diabetic status, and ethnicity were recorded.
RESULTS: The overall average MPOD for the population obtained with the centre-only approach for 56 individuals was 0.400 ± 0.165. The centre-only technique was an accurate predictor of values based on centre and peripheral measures, with 95% limits of agreement of 0.137 OD units. Pearson's correlation coefficient showed a high correlation between right and left eyes (r = 0.7 (p < 0.001)). There was a small difference between males and females that did not reach statistical significance (r = -0.22). There was a non-statistically significant age-related decline in MPOD in this particular population (r = -0.17). Dark irides were significantly associated with high MPOD (r = 0.28, p < 0.05). MPOD in Type II diabetic patients was 27% lower than that in non-diabetics (r = 0.29, p < 0.05).
CONCLUSION: The technique provides similar values of MP optical density to previous reports. As with other HFP-based methods, in a small percentage of older patients, more than one measurement is required before satisfactory results are obtained.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912797     DOI: 10.1007/s00417-013-2430-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  35 in total

1.  A portable instrument for measuring macular pigment with central fixation.

Authors:  J Mellerio; S Ahmadi-Lari; F van Kuijk; D Pauleikhoff; A Bird; J Marshall
Journal:  Curr Eye Res       Date:  2002-07       Impact factor: 2.424

2.  Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors.

Authors:  Johanna M Seddon; Robyn Reynolds; Yi Yu; Mark J Daly; Bernard Rosner
Journal:  Ophthalmology       Date:  2011-09-29       Impact factor: 12.079

3.  Iris color and macular pigment optical density.

Authors:  B R Hammond; K Fuld; D M Snodderly
Journal:  Exp Eye Res       Date:  1996-03       Impact factor: 3.467

4.  Correspondence between retinal reflectometry and a flicker-based technique in the measurement of macular pigment spatial profiles.

Authors:  Rob L P van der Veen; Tos T J M Berendschot; Maria Makridaki; Fred Hendrikse; David Carden; Ian J Murray
Journal:  J Biomed Opt       Date:  2009 Nov-Dec       Impact factor: 3.170

5.  Optical density of the human lens.

Authors:  J Xu; J Pokorny; V C Smith
Journal:  J Opt Soc Am A Opt Image Sci Vis       Date:  1997-05       Impact factor: 2.129

6.  Aging and human macular pigment density. Appended with translations from the work of Max Schultze and Ewald Hering.

Authors:  J S Werner; S K Donnelly; R Kliegl
Journal:  Vision Res       Date:  1987       Impact factor: 1.886

7.  Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973.

Authors:  Stuart P Richer; William Stiles; Kelly Graham-Hoffman; Marc Levin; Dennis Ruskin; James Wrobel; Dong-Wouk Park; Carla Thomas
Journal:  Optometry       Date:  2011-11

Review 8.  Risk factors for age-related maculopathy are associated with a relative lack of macular pigment.

Authors:  John M Nolan; Jim Stack; Orla O' Donovan; Edward Loane; Stephen Beatty
Journal:  Exp Eye Res       Date:  2006-11-01       Impact factor: 3.467

Review 9.  The role of oxidative stress in the pathogenesis of age-related macular degeneration.

Authors:  S Beatty; H Koh; M Phil; D Henson; M Boulton
Journal:  Surv Ophthalmol       Date:  2000 Sep-Oct       Impact factor: 6.048

10.  Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation.

Authors:  J C Khan; D A Thurlby; H Shahid; D G Clayton; J R W Yates; M Bradley; A T Moore; A C Bird
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

View more
  3 in total

1.  Influence of macular oedema on the measurement of macular pigment optical density.

Authors:  Simone Thiele; Franziska Georgia Rauscher; Peter Wiedemann; Jens Dawczynski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-23       Impact factor: 3.117

2.  Associations between macular pigment, iris color and reflectance, ethnicity, and color vision: An observational study.

Authors:  Roya Garakani; Jason S Ng
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

3.  Teaming-up nurses with ophthalmologists to expand the reach of eye care in a middle-income country: Validation of health data acquisition by nursing staff in a telemedicine strategy.

Authors:  Cassia Garcia Moraes Pagano; Tais de Campos Moreira; Daniel Sganzerla; Ana Maria Frölich Matzenbacher; Amanda Gomes Faria; Lucas Matturro; Felipe Cezar Cabral; Dimitris Rucks Varvaki Rados; Anelise Decavata Szortyka; Maicon Falavigna; Maria Eulalia Vinadé Chagas; Erno Harzheim; Marcelo Gonçalves; Roberto Umpierre; Aline Lutz de Araujo
Journal:  PLoS One       Date:  2021-11-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.